Matching articles for "Impavido"
Miltefosine (Impavido) for Leishmaniasis
The Medical Letter on Drugs and Therapeutics • September 15, 2014; (Issue 1451)
The FDA has approved miltefosine (Impavido – Knight
Therapeutics), an oral alkylphosphocholine analog,
for treatment of visceral, cutaneous, and mucosal
leishmaniasis caused by some Leishmania species.
It...
The FDA has approved miltefosine (Impavido – Knight
Therapeutics), an oral alkylphosphocholine analog,
for treatment of visceral, cutaneous, and mucosal
leishmaniasis caused by some Leishmania species.
It is the first drug to be approved by the FDA for
treatment of cutaneous and mucosal leishmaniasis
and the first oral drug to be approved for treatment of
visceral leishmaniasis.
In Brief: Miltefosine for Amebic Meningoencephalitis Available from CDC
The Medical Letter on Drugs and Therapeutics • October 28, 2013; (Issue 1428)
The CDC recently announced that it will now supply the investigational drug miltefosine (Impavido – Paladin, Canada) for treatment of infections caused by free-living amebae.1 The drug was previously...
The CDC recently announced that it will now supply the investigational drug miltefosine (Impavido – Paladin, Canada) for treatment of infections caused by free-living amebae.1 The drug was previously available in the US only from the manufacturer through an FDA Investigational New Drug (IND) application.
Meningoencephalitis caused by the free-living amebae Naegleria fowleri, Acanthamoeba spp., or Balamuthia mandrillaris, usually acquired through the nose while swimming in warm fresh water, has a mortality rate of >90% despite treatment with multiple antimicrobial drugs.2 Miltefosine is active against free-living amebae in vitro, and addition of the drug has improved survival in a small number of patients with Acanthamoeba spp. or B. mandrillaris infection. Infection with N. fowleri is especially severe; of 128 people known to be infected in the US since 1962, only one has survived. Miltefosine has not yet been shown to successfully treat N. fowleri infection.
Miltefosine is also used for treatment of visceral, cutaneous and mucosal leishmaniasis,2 and may soon be approved by the FDA for this indication.
1. CDC. Investigational drug available directly from the CDC for the treatment of infections with free-living amebae. MMWR 2013; 62:666. Available at http://www.cdc.gov. Accessed October 18, 2013.
2. Drugs for parasitic infections.Treat Guidel Med Lett 2013; 11:e1.
Download complete U.S. English article
Meningoencephalitis caused by the free-living amebae Naegleria fowleri, Acanthamoeba spp., or Balamuthia mandrillaris, usually acquired through the nose while swimming in warm fresh water, has a mortality rate of >90% despite treatment with multiple antimicrobial drugs.2 Miltefosine is active against free-living amebae in vitro, and addition of the drug has improved survival in a small number of patients with Acanthamoeba spp. or B. mandrillaris infection. Infection with N. fowleri is especially severe; of 128 people known to be infected in the US since 1962, only one has survived. Miltefosine has not yet been shown to successfully treat N. fowleri infection.
Miltefosine is also used for treatment of visceral, cutaneous and mucosal leishmaniasis,2 and may soon be approved by the FDA for this indication.
1. CDC. Investigational drug available directly from the CDC for the treatment of infections with free-living amebae. MMWR 2013; 62:666. Available at http://www.cdc.gov. Accessed October 18, 2013.
2. Drugs for parasitic infections.Treat Guidel Med Lett 2013; 11:e1.
Download complete U.S. English article
Drugs for Parasitic Infections
The Medical Letter on Drugs and Therapeutics • August 16, 2004; (Issue 1189)
Parasitic infections are found throughout the world. With increasing travel, immigration, use of immunosuppressive drugs and the spread of AIDS, physicians anywhere may see infections caused by previously...
Parasitic infections are found throughout the world. With increasing travel, immigration, use of immunosuppressive drugs and the spread of AIDS, physicians anywhere may see infections caused by previously unfamiliar parasites. The table below lists first-choice and alternative drugs for most parasitic infections. The brand names and manufacturers of the drugs are listed in this article.